Prof Mariana Brandão, medical oncologist at Institute Jules Bordet, Hôpital Universitaire de Bruxelles presents a phase I/IIa study that aims to investigate the efficacy and safety of dry powder inhaled cisplatin in stage IV NSCLC patients.

With the educational support of:

You may also be interested in:

FLAURA2 post-progression outcomes

ELCC 2024 Daily highlight 3

A propensity-based analysis of SBRT & VATS for early-stage lung cancer

Tags:

poster